Apex Biotechnology (Taiwan) Performance
| 1733 Stock | TWD 30.90 0.10 0.32% |
Apex Biotechnology has a performance score of 7 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.0432, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Apex Biotechnology are expected to decrease at a much lower rate. During the bear market, Apex Biotechnology is likely to outperform the market. Apex Biotechnology Corp right now shows a risk of 1.11%. Please confirm Apex Biotechnology Corp semi deviation, coefficient of variation, and the relationship between the mean deviation and downside deviation , to decide if Apex Biotechnology Corp will be following its price patterns.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Apex Biotechnology Corp are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Apex Biotechnology may actually be approaching a critical reversion point that can send shares even higher in March 2025. ...more
| Begin Period Cash Flow | 786.9 M | |
| Total Cashflows From Investing Activities | -35 M | |
| Free Cash Flow | 153.7 M |
Apex |
Apex Biotechnology Relative Risk vs. Return Landscape
If you would invest 2,905 in Apex Biotechnology Corp on November 2, 2024 and sell it today you would earn a total of 185.00 from holding Apex Biotechnology Corp or generate 6.37% return on investment over 90 days. Apex Biotechnology Corp is generating 0.1126% of daily returns and assumes 1.1138% volatility on return distribution over the 90 days horizon. Simply put, 9% of stocks are less volatile than Apex, and 98% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Apex Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apex Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Apex Biotechnology Corp, and traders can use it to determine the average amount a Apex Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1011
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | 1733 | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.11 actual daily | 9 91% of assets are more volatile |
Expected Return
| 0.11 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Apex Biotechnology is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Apex Biotechnology by adding it to a well-diversified portfolio.
Apex Biotechnology Fundamentals Growth
Apex Stock prices reflect investors' perceptions of the future prospects and financial health of Apex Biotechnology, and Apex Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Apex Stock performance.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0434 | |||
| Profit Margin | 0.1 % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 2.45 B | |||
| Shares Outstanding | 99.95 M | |||
| Price To Earning | 31.02 X | |||
| Price To Book | 1.46 X | |||
| Price To Sales | 1.12 X | |||
| Revenue | 2.13 B | |||
| EBITDA | 293.14 M | |||
| Cash And Equivalents | 523.23 M | |||
| Cash Per Share | 5.25 X | |||
| Total Debt | 526.89 M | |||
| Debt To Equity | 31.40 % | |||
| Book Value Per Share | 17.73 X | |||
| Cash Flow From Operations | 179.87 M | |||
| Earnings Per Share | 2.17 X | |||
| Total Asset | 2.67 B | |||
| Retained Earnings | 617 M | |||
| Current Asset | 1.76 B | |||
| Current Liabilities | 638 M | |||
About Apex Biotechnology Performance
Evaluating Apex Biotechnology's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Apex Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Apex Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Apex Biotechnology Corp. engages in the research, development, manufacture, and sale of medical devices by using biosensor technology worldwide. Apex Biotechnology Corp. was founded in 1997 and is headquartered in Hsinchu, Taiwan. APEX BIOTECHNOLOGY operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange.Things to note about Apex Biotechnology Corp performance evaluation
Checking the ongoing alerts about Apex Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Apex Biotechnology Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Apex Biotechnology is not yet fully synchronised with the market data | |
| About 16.0% of the company shares are owned by insiders or employees |
- Analyzing Apex Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Apex Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Apex Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Apex Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Apex Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Apex Biotechnology's stock. These opinions can provide insight into Apex Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Apex Stock Analysis
When running Apex Biotechnology's price analysis, check to measure Apex Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apex Biotechnology is operating at the current time. Most of Apex Biotechnology's value examination focuses on studying past and present price action to predict the probability of Apex Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apex Biotechnology's price. Additionally, you may evaluate how the addition of Apex Biotechnology to your portfolios can decrease your overall portfolio volatility.